NCT06631989View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 4, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Interventions
DRUG

WSD0922-FU

"Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO"

Trial Locations (12)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

200030

RECRUITING

Shanghai Chest Hospital, Shanghai

200123

RECRUITING

Shanghai East Hospital, Shanghai

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

230031

RECRUITING

Anhui Provincial Hospital, Hefei

250117

RECRUITING

Shandong Cancer Hospital, Jinan

300202

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310006

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

317000

RECRUITING

Taizhou Hospital of Zhejiang Province, Taizhou

450000

RECRUITING

He'nan Cancer Hospital, Zhengzhou

510062

RECRUITING

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

610041

RECRUITING

Sichuan Provincial Cancer Hospital, Chengdu

All Listed Sponsors
lead

Wayshine Biopharm, Inc.

INDUSTRY